Navigation Links
ChromaDex Licenses Green Chemistry Technology to Manufacture a New Class of Super Fruit Compounds
Date:7/21/2008

Anthocyanins, leucoanthocyanidins and anthocyanidins are natural,

plant-based colorants with strong antioxidant properties

IRVINE, Calif., July 21 /PRNewswire-FirstCall/ -- ChromaDex Corp., (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, announced today its wholly owned subsidiary has entered into a world-wide license agreement with The Research Foundation of the State University of New York, on behalf of the University at Buffalo (SUNY Buffalo), to produce and market three classes of plant-based ingredients for nutraceutical, functional food, beverage, natural chemical, cosmetic and pharmaceutical industries. Under the terms of the agreement, ChromaDex made an up-front cash payment to SUNY Buffalo and will pay earned royalties on sales of covered technology products and services.

"Anthocyanins are botanically-derived compounds that represent the next 'super fruit' class of phytochemical ingredients," said Frank L. Jaksch Jr., co-founder and CEO of ChromaDex. "This novel and 'green' technology will enable ChromaDex to selectively and cost-effectively manufacture these ingredients and make them commercially available for the first time."

'Green' Ingredients

The technology licensed to ChromaDex includes methods to selectively manufacture anthocyanins, leucoanthocyanidins and anthocyanidins, which are naturally occurring pigments and antioxidants that can be used as natural colorants and may also aid in controlling blood glucose levels to assist with weight management and conditions such as diabetes. Like resveratrol, a super fruit compound that has created extraordinary excitement, anthocyanins are also found in red wine and are even more likely to be responsible for the "French paradox."

"We have been able to develop these molecules for the first time through a proprietary application," said Dr. Mattheos Koffas, assistant professor of chemical engineering at SUNY Bu
'/>"/>

SOURCE ChromaDex Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
2. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
3. NuVasive Licenses Its Insert and Rotate Technology
4. GeneGo Licenses MetaCore Data Analysis Suite to AVEO Pharmaceuticals
5. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
6. Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics
7. HealthTek Software Solutions Licenses First DataBanks OrderView Med Knowledge Base(TM) to Streamline Medication Selection, Management and Reconciliation
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. SuperArray Bioscience Corporation Licenses RNA Interference Patent From The Carnegie Institution
10. Cyberonics Licenses Obesity-Related Patents
11. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
(Date:10/22/2014)... Two sisters in high school have developed ways to ... Krishen use electronic stethoscopes, which electronically amplify body sounds, ... or heartbeats. Ilina, a senior at Port Huron ... way to detect early lung damage in people exposed ... recorded one breath cycle each from 16 smokers, 25 ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is ... repair a damaged mitral valve as the heart continues ... by Abbott Vascular , is designed to treat ... in which the heart’s mitral valve leaflets fail to ... heart’s left ventricle into the left atrium. The heart ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... 21 Patient Safety Week was March 8-14. ... (1979), the pulse oximeter (1983) and the brain activity ... of these technological devices clearly improved patient safety. This ... a forward thinking, caring physician."Until now, I,ve never publicly ...
... MI based company, is researching and developing decontamination testing equipment ... use their extensive knowledge of cleaning and decontamination to develop repeatable ... ... (Vocus) April 21, 2009 -- Midbrook, Inc ., a Jackson, ...
... medical billing company, announces services that help medical professionals go paperless, ... the healthcare industry. , ... (PRWEB) April 21, 2009 ... upon the nation,s healthcare system to step up efforts to convert ...
... worldwide for self-directed home treatment of the most common cause of ... ... Edmonton, Canada (PRWEB) April 14, 2009 -- A new ... treatment of BPPV (Benign Paroxysmal Positional Vertigo), the most common ...
... 21 The University HealthSystem Consortium (UHC) today ... for employee satisfaction surveys and consulting services to ... agreement, which has 2 optional 1-year renewal periods, ... an extensive array of customized surveys and analyses ...
... the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory ... of supplemental new drug applications (sNDA) for SEROQUEL XR (quetiapine ... disorder (MDD) and generalized anxiety disorder (GAD).The Advisory Committee concluded: ... SEROQUEL XR was shown to be ...
Cached Medicine News:Health News:American Society of Anesthesiologists Recent Public Debate Comes to Dead End 2Health News:American Society of Anesthesiologists Recent Public Debate Comes to Dead End 3Health News:Midbrook Tackles Medical Decontamination 2Health News:Midbrook Tackles Medical Decontamination 3Health News:Dr. America Comes to Obama's Aid, Helps Doctors Digitize 2Health News:Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo 2Health News:Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo 3Health News:University HealthSystem Consortium Selects Morehead to Provide Employee Satisfaction and Consulting Services 2Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 2Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 3Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 4Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 5Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 6Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 7
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... 27, 2011 As a result of the flagging ... dangerous to their health, according to Consumer Reports, annual ... take a prescription medicine told pollsters they,d cut health-care ... or medical procedure, declining tests, or ordering cheaper drugs ...
... ( http://www.myprgenie.com ) --  Texans for Stem Cell Research ... panel of stem cell experts from Texas and around ... TSCR Second Annual Educational Symposium with a welcome address ... Health Affairs for The University of Texas System. The ...
Cached Medicine Technology:Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 2Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 3Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 4Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 5World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 2World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 3World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 4World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 5
Malaria device / strip (3 line, P.f/P.v Ag Test-pLDH)...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
BioSign® Malaria - Rapid Malaria Antigen Test...
Medicine Products: